Ysabel Duron is an award-winning journalist, patient advocate, cancer survivor and board member of the California Institute for Regenerative Medicine (CIRM). Her list of achievements continues to grow, as President Biden has appointed Duron to National Cancer Advisory Board (NCAB), which plays an important role in setting the course for the national cancer research program. … Continue reading CIRM board member Ysabel Duron appointed to National Cancer Advisory Board by President Biden
California agency invests $4 million in stem cell treatment for Parkinson’s Disease
The California Institute for Regenerative Medicine (CIRM) is investing $4 million in a late-stage preclinical project by Ryne Bio aiming to improve treatment for Idiopathic Parkinson's disease (PD). PD is characterized by a loss of dopamine producing neurons that result in motor symptoms, such as dyskinesias (involuntary, erratic, writhing movements of the face, arms, legs … Continue reading California agency invests $4 million in stem cell treatment for Parkinson’s Disease
Dr. Vito Imbasciani elected as Chair of California stem cell agency
Dr. Vito Imbasciani will be the new Chair of the California Institute for Regenerative Medicine (CIRM), the state agency created by voters in 2004 and funded again in 2020 to invest in stem cell and regenerative medicine research and treatments. At January’s Board meeting, the agency’s 35-member Governing Board elected Imbasciani to the six-year term, … Continue reading Dr. Vito Imbasciani elected as Chair of California stem cell agency
Investing in a stem cell treatment for Hurler syndrome
The California Institute for Regenerative Medicine (CIRM) awarded $5,444,353 to Dr. Natalia Gomez-Ospina and her team at Stanford University for a late-stage preclinical program targeting Severe Mucopolysaccharidosis type 1, also known as Hurler syndrome. This is an inherited condition caused by a faulty gene. Children with Hurler syndrome lack an enzyme that the body needs to digest … Continue reading Investing in a stem cell treatment for Hurler syndrome
Advancing cutting-edge treatment to improve kidney transplantation in children
Stanford physician-scientist Alice Bertaina, MD, PhD, associate professor of pediatrics has received about $18 million from the California Institute for Regenerative Medicine (CIRM) for a clinical trial to allow kidney transplantation without the need for long-term immunosuppression. Dr. Bertaina and her team at Stanford University were awarded $11,998,188 to test an approach that uses combined … Continue reading Advancing cutting-edge treatment to improve kidney transplantation in children
Investing in CAR T-cell therapy to treat cancer
Photo credit: UC Regents The California Institute for Regenerative Medicine (CIRM) is investing $4 million to support Dr. William Murphy and UC Davis researchers to develop and test a chimeric antigen receptor (CAR) T-cell therapy to treat various B-cell malignancies, ranging from lymphomas to leukemias. In this Q&A—courtesy of UC Davis Health—Dr. Murphy discusses the importance of T-cell therapy and its implications … Continue reading Investing in CAR T-cell therapy to treat cancer
Update on SCID patient enrolled in CIRM-funded gene therapy trial
Photo credit: UCSF Hataalii Tiisyatonii Begay (HT) is paving the road for newborns with SCID. When HT was born in 2018 in a remote part of the Navajo nation, he was quickly diagnosed with a rare and -usually fatal- condition. Today, thanks to a therapy developed at UCSF and funded by CIRM, he’s a healthy … Continue reading Update on SCID patient enrolled in CIRM-funded gene therapy trial
Funding development of a vaccine for acute myelogenous leukemia (AML)
Dr. Karin Gaensler. Photo credit: Steve Babuljak/UCSF Adult acute myelogenous leukemia—also known as acute myeloid leukemia (AML)—is a blood cancer in which the bone marrow makes a large number of abnormal blood cells. About 20,000 new cases of AML are diagnosed each year in the US with a 5-year survival rate of around 29%. In … Continue reading Funding development of a vaccine for acute myelogenous leukemia (AML)
The Most Read Stem Cellar Blog Posts of 2022
This year was a momentous one for the California Institute for Regenerative Medicine (CIRM). You can read some of our achievements in our 2021-2022 annual report. As always, we shared our most exciting updates and newsworthy stories—topics ranging from stem cell research to diversity in science—right here on The Stem Cellar. More than 100,000 blog … Continue reading The Most Read Stem Cellar Blog Posts of 2022
Finding a treatment for Tay-Sachs disease
The California Institute for Regenerative Medicine (CIRM) has awarded $4,048,253 to Dr. Joseph Anderson and his team at UC Davis to develop a blood stem cell gene therapy for the treatment of Tay-Sachs disease. Tay-Sachs disease is a rare genetic disorder where a deficiency in the Hex A gene results in excessive accumulation of … Continue reading Finding a treatment for Tay-Sachs disease
The Stem Cellar 